Literature DB >> 9479876

A case report of a patient who has pure red cell aplasia and rheumatoid arthritis.

C Ustün1, D Karavelioğlu, O Ilhan, O Aydintuğ, M Beksaç.   

Abstract

Pure red cell aplasia (PRCA) as an extra-articular manifestation of rheumatoid arthritis (RA) is rare. In the present report a 40-year-old female patient, with a 4-year-history of severe anemia and pain in the small joints of the hands, was diagnosed as having PRCA by bone marrow (BM) examination. Antithymocyte globulin (ATG), methylprednisolone and cyclosporin A (CSA) were used for the treatment of PRCA. The patient's hematological values responded within 6 months but pre-existing arthralgia continued, although with some relief. The patient subsequently fulfilled the criteria for diagnosis of RA at the 16th month. A review of nine published case reports on the coexistence of PRCA with RA revealed the initial diagnosis as RA. In our case, as the initial symptoms and findings were not sufficient for the diagnosis of RA, we therefore conclude that PRCA preceded RA. Although CSA was curative in the treatment of PRCA it could not prevent the full diagnostic features of RA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9479876

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  5 in total

1.  Pure red cell aplasia in systemic onset juvenile idiopathic arthritis.

Authors:  Priya Sreenivasan; N S Mani
Journal:  Indian J Hematol Blood Transfus       Date:  2011-06-22       Impact factor: 0.900

2.  Pure red cell aplasia caused by ribavirin and interferon treatment.

Authors:  Andrew J Skabelund; Timothy R Hauser; Kevin J Goist
Journal:  Clin J Gastroenterol       Date:  2011-07-30

Review 3.  Immune thrombocytopenic purpura associated with rheumatoid arthritis: case report.

Authors:  Taro Horino; Atsushi Sasaoka; Toshihiro Takao; Takafumi Taguchi; Hiroshi Maruyama; Hiroyuki Ito; Shigeki Takemoto; Hirokuni Taguchi; Kozo Hashimoto
Journal:  Clin Rheumatol       Date:  2005-04-29       Impact factor: 2.980

Review 4.  Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes.

Authors:  Neal S Young
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

5.  Immunosuppressive treatment in patient with pure red cell aplasia associated with chronic myelomonocytic leukemia: harm or benefit?

Authors:  Saloni Tanna; Celalettin Ustun
Journal:  Int J Hematol       Date:  2009-09-18       Impact factor: 2.490

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.